Masimo Corp (NASDAQ: MASI)‘s stock had its “outperform” rating reiterated by Morgan Keegan in a research note issued on Tuesday. They currently have a $26.00 price target on the stock.
Separately, analysts at Brean Murray cut their price target on shares of Masimo Corp from $27.00 to $24.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Analysts at Piper Jaffray (NYSE: PJC) reiterated an “overweight” rating on shares of Masimo Corp in a research note to investors on Tuesday, November 29th. They now have a $31.00 price target on the stock. Also, analysts at Bank of America (NYSE: BAC) initiated coverage on shares of Masimo Corp in a research note to investors on Friday, November 18th. They set an “underperform” rating and a $19.00 price target on the stock.
Masimo Corporation is a medical technology company that develops, manufactures, and markets non-invasive patient monitoring products that improve patient care. The Company invented Masimo Signal Extraction Technology, or Masimo SET, which provides the capabilities of Measure-Through Motion and Low Perfusion pulse oximetry. Pulse oximetry is the non-invasive measurement of the oxygen saturation level of arterial blood, or the blood that delivers oxygen to the body’s tissues, and pulse rate. In addition, the Company offers remote monitoring and clinician notification solutions, such as the Masimo Patient SafetyNet. Its solutions and related products are based upon the Masimo SET algorithms. In July 2010, the Company acquired SEDLine, Inc., a manufacturer of brain function monitoring.
Shares of Masimo Corp opened at 20.04 on Tuesday. Masimo Corp has a one year low of $17.62 and a one year high of $35.15. The stock’s 50-day moving average is $19.22 and its 200-day moving average is $22.80. The company has a market cap of $1.202 billion and a P/E ratio of 18.56.